About Embio
Embio is a Healthcare company based in Mumbai (India) founded in 1986. APIs and chiral intermediates are manufactured by Embio under contract. Embio has raised $50 million across 4 funding rounds from investors including UTI Mutual Fund and True North. The company has 648 employees. Its Indian entity Embio Limited reported revenue of ₹275 Cr. Embio offers products and services including APIs, Intermediates, CDMO Services, and Crop Protection Products. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its competitors include Laurus Labs, Symbiotec and Jubilant Pharma; 2 of its 3 listed competitors have raised funding.
Company details
Embio is engaged in manufacturing APIs and chiral intermediates. It has a portfolio of 24 chiral intermediates and 13 API products. Core competencies include fermentationbiotransformation, chiral chemistry, catalytic hydrogenation and handing controlled substance. It has an array of fermenters 10L, 20L, 50L, 100L, 500L, 1000L, 2000L, 4000L for products of high value and low volume such as enzymes, APIs etc. for satisfying contract manufacturing requirements of its clients. Its manufacturing facility is approved by US-FDA, TGA, WHO-GMP and KFD. It has been complimented by DEA for adhering to documentation systems for controlled substance regulations. It has also been accredited with USP mark and certificate for Pseudoephedrine HCL.
- Headquarters Mumbai, India
- Employees 648
- SectorsHealthcare
- Website embio.co.in
- Social LinkedIn
- Legal Name Embio Limited
- Date of Incorporation 20 Jan, 1986
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹275 Cr
FY 2025 · +49% YoY
- Net Profit₹39.06 Cr
FY 2025 · 14% margin
- EBITDA₹70.85 Cr
FY 2025 · 26% margin
- Total Equity Funding$50M (USD)
in 4 rounds
- Latest Funding Round$50M (USD), Private Equity Round
May 2026
- InvestorsUTI Mutual Fund
& 1 more
- Employee Count648
Associated legal entities of Embio
Embio operates through Embio Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Embio Limited CIN U24110MH1986PLC038680 | Active | 20 Jan 1986 | Mumbai, Maharashtra | ₹275 Cr | 600 | 6 | View details |
Products & Services of Embio
Embio offers a comprehensive portfolio of products and services, including APIs, Intermediates, CDMO Services, and Crop Protection Products.
Active ingredients for drug manufacturing and global supply
Raw materials for chemical synthesis processes
Custom development and manufacturing for client needs
Solutions for crop and plant protection improvement
Funding Insights of Embio
Embio has successfully raised a total of $50M across 4 strategic funding rounds. The most recent funding activity was a Private Equity Round of $50 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $50M
- Total Rounds 4
- Last Round Private Equity Round — $50M
- Investors Count 2
All 4 funding rounds of Embio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2026 | $50M | Private Equity Round | – | – | |
| Oct 2018 | $292,424 | Unspecified | – | – | – |
| Aug 2009 | Unspecified | – | – | – | |
| Sep 2003 | Unspecified | – | UTI Mutual Fund | – |
2 investors in total: 2 institutional.
Investors in Embio
Embio has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include UTI Mutual Fund and True North.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| truenorth.co.in | ||||
Mutual funds, portfolio management, and retirement planning services are offered. | 2001 | utimf.com | Mumbai, India |
Investor details for Embio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Embio Limited (Embio)
Embio Limited is the primary company behind Embio. The board of Embio Limited currently have 5 directors; the longest-serving is Ajit Tekchand Vaswani, appointed in 2001. 13 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ajit Tekchand Vaswani DIN 00057953 | Director | 16 Oct 2001 | 25 yrs | Embio Limited |
| Devesh Malladi DIN 00025221 | Managing Director | 01 Oct 2007 | 19 yrs 1 mo | Embio Limited |
| Madhusudan Rao Garimella DIN 00267548 | Director | 07 Aug 2017 | 9 yrs 3 mo | Embio Limited |
| Raghavachari Kasthuri Rangan DIN 00373554 | Director | 20 Sep 2024 | 2 yrs 1 mo | Embio Limited |
| Aadya Malladi DIN 11180225 | Additional Director | 26 Jun 2025 | 1 yr 4 mo | Embio Limited |
People of Embio
13 people are tracked at Embio (5 in leadership, 5 in board & advisors, 3 in team); the tracked headcount is 648.
| Name | Role | Group |
|---|---|---|
| Managing Director | Leadership | |
M. Devesh | Managing Director | Leadership |
Srinivasa Rao P | Head Of Quality Assurance & Regulatory Affairs | Leadership |
Anand Kumar Jain | Vice President Operations & Technical Services | Leadership |
R.k. Gite | Chief Manager - EHS & Operations | Leadership |
M. H. Avadhani | Chairman | Board & advisors |
Jayant N. Godbole | Non-Executive Director | Board & advisors |
| Non-Executive Director | Board & advisors | |
A.T. Vaswani | Non-Executive Director | Board & advisors |
R.K. Prabhu | Executive Director | Board & advisors |
Krishna G. Kulkarni | Dy. General Marketing Manager | Team |
Yogesh Raje | Senior Human Resources Manager | Team |
Aviraj Sakpal | System Administrator | Team |
Complete people profiles for Embio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Embio
Figures of Embio Limited, the primary company behind Embio, for FY 2025. Revenue was ₹275 Cr (+49% year on year). Net profit was ₹39.06 Cr (14% margin). EBITDA was ₹70.85 Cr (26% margin). Revenue has grown at a compounded annual rate of +20% over three years and +10% over five years.
- ₹275 CrRevenue · FY 2025 · +49% YoY
- ₹39.06 CrNet profit · 14% margin
- ₹70.85 CrEBITDA · 26% margin
- ₹4.70 CrPaid-up capital
- 600Employees (provident fund records)
- +20%Revenue CAGR, 3 years
- +10%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Embio Limited are on its company page.
Detailed financial statements for Embio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Embio
3 dated milestones of Embio across 40 years, from founding to its latest funding, stage changes and deals.
- Founded Embio is founded.
- Funding First funding round.
- Funding Latest funding round, Private Equity Round, of $50.0M.
Competitors of Embio
Embio has 3 listed competitors in our database, 2 of them funded. They include Laurus Labs, Symbiotec and Jubilant Pharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| jubilantpharma.com | 1978 | Noida, India | Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. |
Detailed competitors of Embio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Embio (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Embio
Complete news archive for Embio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Embio
Embio was founded in 1986 and raised its 1st funding round 17 years after it was founded.
Embio is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Embio is a funded company, having raised a total of $50M across 4 funding rounds to date.
Embio has 648 employees.
The primary company behind Embio, Embio Limited, reported revenue of ₹275 Cr for FY 2025, up 49% year on year.
Embio is engaged in manufacturing APIs and chiral intermediates. It has a portfolio of 24 chiral intermediates and 13 API products. Core competencies include fermentationbiotransformation, chiral chemistry, catalytic hydrogenation and handing controlled substance. It has an array of fermenters 10L, 20L, 50L, 100L, 500L, 1000L, 2000L, 4000L for products of high value and low volume such as enzymes, APIs etc. for satisfying contract manufacturing requirements of its clients. Its manufacturing facility is approved by US-FDA, TGA, WHO-GMP and KFD. It has been complimented by DEA for adhering to documentation systems for controlled substance regulations. It has also been accredited with USP mark and certificate for Pseudoephedrine HCL.
Embio's top competitors include Laurus Labs, Symbiotec and Jubilant Pharma.
Embio offers APIs, Intermediates, CDMO Services, and Crop Protection Products.
Embio has 2 investors. Key investors include UTI Mutual Fund, and True North.
Embio operates through Embio Limited.
The legal entities of Embio currently have 6 directors, including Madhusudan Rao Garimella, Ajit Tekchand Vaswani, Devesh Malladi and others.